MICHAEL JAMES OVERMAN to Receptors, Somatomedin
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Receptors, Somatomedin.
Connection Strength
0.275
-
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71.
Score: 0.152
-
Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
Score: 0.123